

Antihyperlipidemic Screening of Polyherbal Formulation of *Annona squamosa* and *Nigella sativa*

Sanjiv Singh^{1*}, F. V. Manvi¹, Basavraj Nanjwade¹, Rajesh Kumar Nema²

¹K. L. E. S's College of Pharmacy, Belgaum-590 010, Karnataka, India

²Rishiraj College of Pharmacy, Sanwer Road, Indore, Madhya Pradesh, India

ABSTRACT

This study was undertaken to investigate the effect of Polyherbal formulation of *Annona squamosa* and *Nigella sativa* on blood glucose, plasma insulin, tissue lipid profile, and lipidperoxidation in streptozotocin induced diabetic rats. Aqueous extract of Polyherbal formulation of *Annona squamosa* and *Nigella sativa* was administered orally (200 mg/kg body weight) for 30 days. The different doses of Polyherbal formulation on blood glucose and plasma insulin in diabetic rats were studied and the levels of lipid peroxides and tissue lipids were also estimated in streptozotocin induced diabetic rats. The effects were compared with tolbutamide. Treatment with Polyherbal formulation and tolbutamide resulted in a significant reduction of blood glucose and increase in plasma insulin. Polyherbal formulation also resulted in a significant decrease in tissue lipids and lipid peroxide formation. The decreased lipid peroxides and tissue lipids clearly showed the antihyperlipidemic and antiperoxidative effect of Polyherbal formulation apart from its antidiabetic effect.

Keywords: Polyherbal formulation, *Annona squamosa*, *Nigella sativa*, Streptozotocin, Antihyperlipidemic activity.

INTRODUCTION

Diabetes mellitus is syndrome, initially characterized by a loss of glucose homeostasis resulting from defects in insulin secretion, insulin action both resulting impaired metabolism of glucose and other energy yields fuels such as lipids and protein¹. Experimental diabetes in animals has provided considerable insight into the physiologic and biochemical derangement of the diabetic state. Many of the derangement have been characterized in hyperglycemic animals. Significant changes in lipid metabolism and structure also occur in diabetes². In these cases the structural changes are clearly oxidative in nature and are associated with development of vascular disease in diabetes³. In diabetic rats, increased lipidperoxidation was also associated with hyperlipidemia⁴. Liver, an insulin dependent tissue that plays a pivotal role in glucose and lipid homeostasis and it is severely affected during diabetes⁵.

Liver and kidney participates in the uptake, oxidation and metabolic conversion of free fatty acids, synthesis of cholesterol, phospholipids, and triglycerides. During diabetes, a profound alteration in the concentration and composition of lipids occurs. Despite the great strides that have been made in the understanding and management of diabetes, the disease and disease related complications are increasing unabated⁶. In spite of the presence of known antidiabetic medicine in the pharmaceutical market, remedies

from medicinal plants are used with success to treat this disease⁷. Many traditional plant treatments for diabetes are used throughout the world. Plant drugs⁸ and herbal formulation^{9, 10, 11} are frequently considered to be less toxic and freer from side effects than synthetic one.

Based on the WHO recommendations hypoglycemic agents of plant origin used in traditional medicine are important (WHO, 1980). The attributed antihyperglycemic effects of these plants is due to their ability to restore the function of pancreatic tissues by causing an increase in insulin output or inhibit the intestinal absorption of glucose or to the facilitation of metabolites in insulin dependent processes. Hence treatment with herbal drugs has an effect on protecting b-cells and smoothing out fluctuation in glucose Levels^{12, 13}. In general, there is very little biological knowledge on the specific modes of action in the treatment of diabetes, but most of the plants have been found to contain substances like glycosides, alkaloids, terpenoids, flavonoids etc., that are frequently implicated as having antidiabetic effects¹⁴.

In the traditional system of Indian medicine, plant formulation and combined extracts of plants are used as drug of choice rather than individual. Various herbal formulations such as diamed¹⁵, coagent db¹⁶, Diasulin¹⁷ and hyponidd¹⁸, are well known for their antidiabetic effects. Polyherbal formulation of *Annona squamosa* and *Nigella sativa* is composed of medicinal plants (Table 1), which are traditionally used for antidiabetic and antihyperlipidemic activity^{19, 20}. The present investigation was undertaken to study the effect of the Polyherbal formulation of *Annona squamosa* and *Nigella sativa* on lipidperoxidation and tissue

*Corresponding author: Mr. Sanjiv Singh,
K. L. E. S's College of Pharmacy, Belgaum-590 010,
Karnataka, India; E-mail: sanjivpg2006@yahoo.com

lipid profile in streptozotocin induced diabetic rats. The effects produced by this formulation on different parameters were compared with tolbutamide, a reference drug.

MATERIAL AND METHODS

Animals

Male Wistar albino rats (weighing 160–200 g) were procured from Venkateshwara Enterprise, Bangalore and they kept in under standard environmental conditions (12 h light/dark cycles at 25–28 °C, 60–80% relative humidity) in clean and dry cages and maintained in well-ventilated animal house. Animals were divided into 8 groups of five each and were fed with standard diet and water *ad libitum*. The study was approved by the Institutional Animal Ethics Committee.

Preparation of drug

The seeds of *Nigella sativa* obtained from Prgati Ayurvedic Drug store Belgaum and matured fruit of *Annona squamosa* from local market of Belgaum and they were authenticated from Botanical Survey of India, Pune (Maharashtra). The extracts of the both antidiabetic plants were mixed and polyherbal formulation was prepared (Table 1). Five hundred grams of each plant (chopped into small pieces) was extracted individually and were soaked overnight in 1 l of water. This suspension was filtered and the filtrates were pooled and the solvents were evaporated in a rotavapor at 40–50 °C under reduced pressure and lyophilized²¹.

Chemicals

Streptozotocin and other biochemicals used in this experiment were purchased from Sigma Chemical Company Inc., St. Louis, Mo, and USA. Enzyme linked immunosorbant assay (ELISA) kit for insulin assay was purchased from Boehringer Mannheim, Germany. Tolbutamide was a generous gift sample from Sun Pharmaceuticals Limited, Baroda, India. All other chemicals used were of analytical grade.

Drug administration

Polyherbal formulation of *Annona squamosa* and *Nigella sativa* was suspended in distilled water and administered orally through intragastric tube at the following doses of 50, 100 and 200 mg/kg body weight.

Streptozotocin-induced diabetes

Rats were made diabetic by single administration of streptozotocin (60 mg/kg/i.p) dissolved in 0.1 M-citrate buffer, pH 4.5. Forty-eight hours later, blood samples were collected and glucose levels were determined to confirm the development of diabetes. Only those animals which showed hyperglycemia (blood glucose levels > 300 mg/dl) were used in the experiment.

Experimental design

In the experiment, a total of 42 rats (30 diabetic surviving rats, 12 normal rats) were used. The rats were divided into seven groups of six rats each after the induction of streptozotocin diabetes.

Group 1: Normal treated rats.

Group 2: Normal rats given aqueous solution of Polyherbal formulation (200 mg/kg body weight) daily using an intragastric tube for 30 days.

Group 3: Diabetic control rats.

Group 4: Diabetic rats given aqueous solution of Polyherbal formulation (50 mg/kg body weight) daily using an intragastric tube for 30 days.

Group 5: Diabetic rats given aqueous solution of Polyherbal formulation (100 mg/kg body weight) daily using an intragastric tube for 30 days.

Group 6: Diabetic rats given aqueous solution of Polyherbal formulation (200 mg /kg body weight) daily using an intragastric tube for 30 days.

Group 7: Diabetic rats given aqueous solution of Tolbutamide (250 µg/kg bodyweight) daily use an intragastric tube for 30 days.

At the end of 30 days, all the rats were killed by decapitation under pentobarbitone sodium (60 mg/kg) anesthesia. Blood was collected in tubes containing potassium oxalate and sodium fluoride solution for the estimation of blood glucose and plasma was separated for the assay of insulin. Liver and kidney were immediately dissected out, washed in ice-cold saline to remove the blood. The tissues were weighed and 10% tissue homogenate was prepared with 0.025 M Tris–HCl buffer, pH 7.5. After centrifugation at 3000 rpm for 10 min, the clear supernatant was used to measure thiobarbituric acid reactive substances (TBARS) and hydroperoxides. For the determinations of lipids the liver and kidney tissues were weighed and lipids were extracted from tissues²².

Biochemical analysis

Estimation of blood glucose and plasma insulin

Blood glucose was determined by the O-toluidine method²³. Plasma insulin was assayed by ELISA, using Boehringer-Mannheim Kit with a Boehringer analyzer ES300.

Estimation of lipid peroxidation

Lipid peroxidation in liver and kidney were estimated colorimetrically by thiobarbituric acid reactive substances TBARS²⁴ and hydroperoxides²⁵). In brief, 0.1 ml of tissue homogenate (Tris–HCl buffer, pH 7.5) was treated with 2 ml of (1:1:1 ratio) TBA–TCA–HCl reagent (thiobarbituric acid 0.37%, 0.25 N HCl and 15% TCA) and placed in water bath for 15 min, cooled. The absorbance of clear supernatant was measured against reference blank at 535 nm. 0.1 ml of tissue homogenate was treated with 0.9 ml of Fox reagent (88 mg butylated hydroxytoluene (BHT), 7.6 mg xylenol orange and 9.8 mg ammonium ion sulphate were added to 90 ml of methanol and 10 ml 250 mM sulphuric acid) and incubated at 37 °C for 30 min. The colour developed was read at 560 nm colorimetrically. Hydroperoxides was expressed as mM/100 g tissue.

Estimation of lipids

Lipids were extracted from tissues by the method of using chloroform–methanol mixture²² (CHCl₃:MeOH) (2:1 v/v).

For total cholesterol estimation²⁶ 0.1 ml of the lipid extract, 9.9 ml of ferric chloride–acetic acid reagent was added and allowed to stand for 15 min and then centrifuged. To 5 ml of the supernatant, add 3 ml of Conc. H₂SO₄. The colour developed was read after 20 min at 560 nm against a reagent blank. Values were expressed as mg/100 g tissue.

For Triglycerides estimation²⁷ an aliquot of lipid extract, evaporated to dryness. 0.1 ml of methanol was added followed by 4 ml of isopropanol. 0.4 g of alumina was added to all the tubes and shaken well for 15 min. Centrifuged and then 2 ml of the supernatant was transferred to labeled tubes. The tubes were placed in a water bath at 65 °C for 15 min for saponification after adding 0.6 ml of the saponification reagent followed by 0.5 ml of acetyl acetone reagent. After mixing, the tubes were kept in a water bath at 65 °C for 1 h, the contents were cooled and absorbance was read at 420 nm. The triglyceride content was expressed as mg/100 g tissue.

Phospholipid content was determined²⁸ by 0.1 ml of lipid extract, added 1 ml of 5 N H₂SO₄ and 1 ml of Conc. HNO₃ and digested to a colourless solution. The phosphorus content

in the extract was determined²⁹. The values were expressed as g/100 tissue.

Free Fatty acids were estimated³⁰ by 0.1 ml of lipid extract was evaporated to dryness. One milliliter of phosphate buffer, 6 ml of extraction solvent and 2.5 ml of copper reagent were added. All the tubes were shaken vigorously. Two hundred milligrams of activated silicic acid was added and left aside for 30 min. The tubes were centrifuged and 3 ml of the copper layer was transferred to another tube containing 0.5 ml of diphenyl carbazide and mixed carefully. The absorbance was read at 550 nm immediately. The amount of free fatty acids was expressed as mg/100 g tissue.

Statistical analysis

The data for various biochemical parameters were analyzed using analysis of variance (ANOVA) and the group means were compared by Duncan's Multiple Range Test (DMRT). Values were considered statistically significant when at $p < 0.05$ ³¹.

Table 1: Polyherbal Formulation of *Annona Squamosa* and *Nigella Sativa* (Composition and Concentration).

S. No.	Botanical Name	Common Name	Family	Part used	Conc. (%)
1	<i>Annona squamosa</i>	Sharifa	Annonaceae	Matured fruits	50
2	<i>Nigella sativa</i>	Kalonji	Ranunculaceae	Seeds	50

Table 2: Changes in blood glucose and plasma insulin levels of control and experimental animals.

Group	Fasting blood glucose (mg/dl)	Plasma insulin (IU/ml)
Normal	81.04 ± 2.29	11.26 ± 0.96
Diabetic control	262.24 ± 22.23	3.48 ± 0.69
Diabetic + Polyherbal formulation (50 mg/kg)	209.58 ± 12.46	5.59 ± 0.34
Diabetic + Polyherbal formulation (100 mg/kg)	155.58 ± 11.69	6.03 ± 0.45
Diabetic + Polyherbal formulation (200 mg/kg)	104.16 ± 6.56	7.15 ± 0.45
Diabetic + Tolbutamide (250 mg/kg)	110.65 ± 9.35	6.32 ± 0.48

Values are given as mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at $p < 0.05$ (DMRT).

RESULTS

Table 2 shows the level of blood glucose and plasma insulin in control and experimental diabetic animals. There was a significant elevation in blood glucose level with significant decrease in plasma insulin levels in streptozotocin diabetic rats, compared with normal rats. Administration of Polyherbal formulation and Tolbutamide tended to bring blood glucose and plasma insulin towards near normal levels. The effect of Polyherbal formulation at 200 mg/kg was significantly better than 50 and 100 mg/kg; therefore the higher dose was used for further biochemical studies. The administration of Polyherbal formulation and Tolbutamide to normal rats showed a significant effect in lowering blood glucose and increasing plasma insulin.

Table 3 represents the concentration of TBARS and Hydroperoxides in tissues of control and experimental animals. There was a significant elevation in tissue TBARS and Hydroperoxides during diabetes, when compared to the corresponding control group. Administration of Polyherbal formulation and Tolbutamide tends to bring the values to near normal.

Table 3: Changes in levels of TBARS and Hydroperoxides in liver and kidney of control and experimental animals (mm/100 g tissue).

Groups	TBARS		Hydro peroxide	
	Liver	Kidney	Liver	Kidney
Normal	0.58 ± 0.066	0.68 ± 0.05	70.38 ± 4.54	55.34 ± 4.55
Normal + Polyherbal formulation (200 mg/kg)	0.56 ± 0.079	0.78 ± 0.06	68.59 ± 5.14	52.48 ± 4.75
Diabetic control	1.54 ± 0.06	1.65 ± 0.12	99.98 ± 5.98	78.29 ± 4.58
Diabetic + Polyherbal formulation (200 mg/kg)	0.64 ± 0.053	0.97 ± 0.07	80.55 ± 5.69	60.99 ± 4.78
Diabetic + Tolbutamide (250 mg/kg)	0.67 ± 0.088	1.02 ± 0.08	84.35 ± 5.45	62.45 ± 5.56

Values are given as mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at $p < 0.05$ (DMRT).

Table 4: Changes in levels of cholesterol, free fatty acids, triglycerides and phospholipids in liver of control and experimental animals (mg/100 g wet tissue).

Groups	Cholesterol	Free fatty acids	Triglycerides	Phospholipids
Normal	335.44 ± 18.90	606.10 ± 1.76	344.50 ± 23.20	1598.00 ± 19.30
Normal + Polyherbal formulation (200 mg/kg)	328.38 ± 5.74	601.93 ± 9.00	341.10 ± 21.00	1593.10 ± 24.10
Diabetic control	496.56 ± 13.10	921.60 ± 44.60	622.50 ± 18.80	1858.60 ± 18.70
Diabetic + Polyherbal formulation (200 mg/kg)	398.65 ± 17.54	769.16 ± 3.30	456.25 ± 17.30	1718.80 ± 14.40
Diabetic + Tolbutamide (250 mg/kg)	405.21 ± 9.79	802.80 ± 3.77	530.80 ± 35.70	1769.30 ± 17.60

Values are given as mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at $p < 0.05$ (DMRT).

Table 5: Changes in levels of cholesterol, free fatty acids, triglycerides and phospholipids in kidney of control and experimental animals (mg/100 g wet tissue).

Groups	Cholesterol	Free fatty acids	Triglycerides	Phospholipids
Normal + Polyherbal formulation (200 mg/kg)	371.08 ± 8.28	432.51 ± 1.60	278.75 ± 14.60	1442.50 ± 43.30
Diabetic control	546.90 ± 23.80	743.00 ± 5.70	501.10 ± 34.10	2041.50 ± 33.60
Diabetic + Polyherbal formulation (200 mg/kg)	435.20 ± 12.18	556.80 ± 8.50	382.90 ± 9.28	1684.00 ± 28.80
Diabetic + Tolbutamide (250 mg/kg)	449.90 ± 13.49	600.30 ± 3.40	438.66 ± 39.30	1819.30 ± 34.70

Values are given as mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at $p < 0.05$ (DMRT).

Table 4 and 5 show the levels of cholesterol, triglycerides, free fatty acids and phospholipids in liver and kidney of control and experimental rats, respectively. Liver and kidney of diabetic rats showed significantly increased levels of cholesterol, triglycerides, free fatty acids and phospholipids, when compared with normal rats. In rats treated with Polyherbal formulation and Tolbutamide there was a

significant decrease in the content of cholesterol, triglycerides, free fatty acids and phospholipids in both the tissues, when compared with diabetic control rats.

DISCUSSION

Diabetes mellitus is one of the most common chronic disease and is associated with hyperlipidemia and co-morbidities such as obesity, hypertension. Hyperlipidemia is a metabolic complication of both clinical and experimental diabetes³². Streptozotocin induces a wide variety of animal species by damaging the insulin secreting pancreatic β -cell, resulting in a decrease in endogenous insulin release, which paves the ways for the decreased utilization of glucose by the tissues³³. In our study, we have observed that Polyherbal formulation decreases blood glucose in streptozotocin diabetic rats. The possible mechanism of action of extract could be correlated with the reminiscent effect of the hypoglycemic sulphonylureas that promote insulin secretion by closure of K^+ -ATP channels, membrane depolarization and stimulation of Ca^{2+} influx, an initial key step in insulin secretion. In this context, number of other plants has also been reported to have antihyperglycemic and insulin stimulatory effects^{34, 35}. Like the plant extract, tolbutamide also produced significant reduction in blood glucose levels of streptozotocin diabetic rats.

Since streptozotocin is known to destroy pancreatic β -cells, the present findings appear to be in consonance with the earlier suggestion³⁶ that sulphonylureas have extrapancreatic antihyperglycemic mechanism of action secondary to their insulin secreting effect and the attendant glucose uptake into, and utilization by, the tissues.

Apart from the regulation of carbohydrate metabolism, insulin also plays an important role in the metabolism of lipids. Insulin is potent inhibitor of lipolysis. Since it inhibits the activity of the hormone sensitive lipases in adipose tissue and suppresses the release of free fatty acids³⁷. During diabetes, enhanced activity of this enzyme increases lipolysis and releases more free fatty acids into the circulation³⁸. Increased fatty acids concentration also increases the β -oxidation of fatty acids, producing more acetyl CoA and cholesterol during diabetes. In normal condition, insulin increases the receptor-mediated removal of LDL-cholesterol and decreased activity of insulin during diabetes causes hypercholesterolemia. Hypercholesterolemia and hypertriglyceridemia have been reported to occur in diabetic rats³⁹. The increased concentration of cholesterol could result in a relative molecular ordering of the residual phospholipids resulting in a decrease in membrane fluidity⁴⁰.

The increased concentration of free fatty acids in liver and kidney may be due to lipid breakdown and this may cause increased generation of NADPH, which results in the activation of NADPH dependent microsomal lipid peroxidation. Liver and kidney phospholipids were increased in diabetic control rats. Phospholipids is present in cell membrane and make up vast majority of the surface lipoprotein forming a lipid bilayer that acts as an interface with both polar plasma environment and non-polar lipoprotein of lipoprotein core⁴¹.

Phospholipids are vital part of biomembrane rich in PUFA, which are susceptible substrate for free radicals such as O_2^- and OH. Radicals⁴². Increased phospholipids levels in tissues were reported^{43,44} in streptozotocin diabetic rats. Administration of Polyherbal formulation decreased the levels of tissue free fatty acids and phospholipids.

Accumulation of triglycerides is one of the risk factors in Coronary Heart Disease (CHD). The significant increase in the level of triglycerides in liver and kidney of diabetic control rats may be due to the lack of insulin. Since under normal condition, insulin activates the enzyme lipoprotein lipase and hydrolysis triglycerides⁴⁵. Polyherbal formulation reduces triglycerides in tissues of streptozotocin-induced diabetic rats and may prevent the progression of CHD. The results show increased lipid peroxidation in the tissues (liver and kidney) of diabetic control group. Previous studies have reported that there was an increased lipid peroxidation in liver, heart, kidney and brain of diabetic rats^{46, 47}. This may be because the tissues contain relatively high concentration of easily peroxidizable fatty acids.

Liver during diabetes, showed a relatively severe impairment in antioxidant capacity than kidney. The kidney exhibits a characteristic pattern of changes during diabetes⁴⁸. The increase in oxygen free radicals in diabetes could be primarily due to increase in blood glucose levels, which upon autoxidation generate free radicals and secondarily due to the effects of diabetogenic agent streptozotocin⁴⁹. In diabetes, hypoinsulinaemia increases the activity of the enzyme, fatty acyl coenzyme, coenzyme A oxidase, which initiates β -oxidation of fatty acids resulting in lipid peroxidation^{50, 51}.

Increased lipid peroxidation impairs membrane functions by decreasing membrane fluidity, and changing the activity of membrane-bound enzymes⁵¹. Its products (lipid radicals and lipid peroxide) are harmful to the cells in the body and are associated with atherosclerosis and brain damage⁵¹. Administration of Polyherbal formulation and Tolbutamide reduced the lipid peroxidative markers in liver and kidney tissues of diabetic rats. This indicates that Polyherbal formulation inhibit oxidative damage due to the effect of ingredients present in Polyherbal formulation. This could be correlated with previous study that reported that *Annona squamosa* and *Nigella sativa* antihyperlipidemic effect of diabetic animals. Antidiabetic and antihyperlipidemic effect of Polyherbal formulation of *Annona squamosa* and *Nigella sativa* may be due to the effect of active constituents of both plants alkaloid, phytosterols, which may be responsible for scavenging free radicals liberated by streptozotocin in diabetic rats. On the basis of above results, it could be concluded that Polyherbal formulation of *Annona squamosa* and *Nigella sativa*, exert a significant antihyperlipidemic. This could be due to combined effect of *Annona squamosa* and *Nigella sativa*. Hence the antihyperlipidemic effect of Polyherbal formulation of *Annona squamosa* and *Nigella sativa* in particular could be considered as of possible therapeutic value.

ACKNOWLEDGMENTS

Authors are thankful to KLESs College of Pharmacy, Belgaum for providing necessary facilities to conduct the experimental work.

REFERENCES

1. Scheen, J.A., Drug treatment of non-insulin dependent diabetes mellitus in the 1990s. Achievements and future development. *Drug*, 1997, 54, 355–368.
2. Sochar, M., Baquer, N.Z., Mclean, P., Glucose under utilization in diabetes. Comparative studies on the changes in the activities of enzymes of glucose metabolism in rat kidney and liver. *Mol. Physiol.* 1985, 7, 51–68.
3. Baynes, J.W., Thrope, S.R., Role of oxidative stress in diabetic complications. *Diabetes*, 1999, 48, 1–4.

4. Morel, D.W., Chisolm, G.M., Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. *J. Lipid Res.* 1989. 30, 1827–1834.
5. Seifter, S., England, S., Energy metabolism. In: Arias, I., Papper, M., Schacter, D. (Eds.), *The Liver; Biology and Pathology*. Raven Press, New York, 1982. pp. 219–249.
6. Tiwari, A.K., Madhusudana Rao, J., Diabetes mellitus and multiple therapeutic approaches of phytochemicals: present status and future prospects. *Curr. Sci.* 2002. 83, 30–38.
7. Bhattaram, V.A., Ceraefe, M., Kohlest, C., Vest, M., Deundorf, H., Pharmacokinetics and bioavailability of herbal medicinal products. *Phytomedicine*. 2002. 9, 1–36.
8. Bailey, C.J., Day, C., Traditional treatments for diabetes. *Diab. Care* 1989. 12, 553–564.
9. Mitra, S.K., Gopumadhavan, S., Muralidhar, T.S., Anturlikar, S.D., Sujatha, M.B., Effect of a herbomineral preparation D-400 in streptozotocin induced diabetic rats. *J. Ethnopharmacol.* 1996. 54, 41–46.
10. Annapurna, A., Kanaka, S., Mahalakshmi, D., Murali Krishna, K., Antidiabetic activity of a polyherbal preparation (tincture of punchparna) in normal and diabetic rats. *Indian J. Exp. Biol.* 2001. 39, 500–502.
11. Bhattacharya, S.K., Satyan, K.S., Chakraborti, A., Effect of trasina, an ayurvedic herbal formulation, on pancreatic islet superoxide dismutase activity in hyperglycaemic rats. *Indian J. Exp. Biol.* 1997. 35, 297–299.
12. Jia, W., Gao, W.Y., Xiao, P.G., Antidiabetic drugs of plant origin used in China: composition, pharmacology and hypoglycemic mechanisms. *Zhongguo Zhong Yao Za Zhi* 2003. 28, 108–113.
13. Elder, C., Ayurveda for diabetes mellitus: a review of the biomedical literature. *Alter. Ther. Helt. Med.* 2004. 10, 44–50.
14. Loew, D., Kaszkin, M., Approaching the problem of bioequivalence of herbal medicinal products. *Phytother. Res.* 2002. 16, 705–711.
15. Pari, L., Ramakrishnan, R., Venkateswaran, S., Antihyperglycaemic effect of diamed, an herbal formulation in experimental diabetes in rats. *J. Pharma. Pharmacol.* 2001. 53, 1139–1143.
16. Pari, L., Saravanan, G., Antidiabetic effect of coagent db, a herbal drug in alloxan induced diabetes mellitus. *Comp. Biochem. Physiol. Part C* 2002. 131, 19–25.
17. Pari, L., Saravanan, R., Antidiabetic effect of diasulin, an herbal drug, on blood glucose, plasma insulin and hepatic enzymes of glucose metabolism in hyperglycemic rats. *Diab. Obes. Met.* 2004. 6, 286–292.
18. Subash Babu, P., Prince, P.S.M., Antihyperglycaemic and antioxidant effect of hyponidd an ayurvedic herbomineral formulation in streptozotocin induced diabetic rats. *J. Pharma. Pharmacol.* 2004. 56, 1435–1442.
19. Meral, I., Z. Yener, T. Kaharman and N. MERT, Effect of nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant, defense system and liver damage in experimentally-induced diabetic rabbits. *J. Med. A. Physiol. Patho. Clin. Med.*, 2001. 48; 593-599.
20. Rajesh KG. Achyut NK. Hypoglycaemic and antidiabetic effect of aqueous extract of leaves of *Annona squamosa* (L.) in experimental animal. *Current Science*, Vol. 88. 2005; 1244-1254.
21. Pandey, V.N., Rajagopalan, S.S., Chowdhorry, D.P., An effective ayurvedic hypoglycemic formulation. *J. Res. Ayur. Siddha* 1995. 16, 1–14.
22. Folch, J., Lees, M., Solane, S.G.H., A simple method for isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* 1957. 226, 497–509.
23. Sasaki, T., Matsy, S., Sonae, A., Effect of acetic acid concentration on the colour reaction in the O-toluidine boric acid method for blood glucose estimation. *Rinshobokagaku* 1972. 1, 346–353.
24. Niehius, W.G., Samuelsson, D., Formation of malondialdehyde from phospholipid arachidonate during microsomal lipidperoxidation. *Eur. J. Biochem.* 1968. 6, 126–130.
25. Jiang, Z.Y., Hunt, J.V., Wolft, S.D., Ferrous ion oxidation in the presence of xynelol orange for detection of lipid hydroperoxide in low-density lipoprotein. *Anal. Biochem.* 1992. 202, 384–389.
26. Zlatkis, A., Zak, B., Boyle, G.J., A method for the determination of serum cholesterol. *J. Clin. Med.* 1953. 41, 486–492.
27. Foster, J.B., Dunn, R.T., Stable reagents for determination of serum triglyceride by colorimetric condensation method. *Clin. Chim. Acta* 1973. 19, 338–340.
28. Zilversmit, B.B., Davis, A.K., Micro determination of plasma phospholipids by TCA precipitation. *J. Lab. Clin. Med.* 1950. 35, 155–160.
29. Fiske, C.H., Subbarow, J., The colorimetric determination of phosphorus. *J. Biol. Chem.* 1925. 66, 375–400.
30. Falholt, K., Falholt, W., Lund, B., An assay colorimetric method for routine determination of free fatty acids in plasma. *Clin. Chim. Acta* 1973. 46, 105–111.
31. Duncan, B.D., Multiple range test for correlated and heteroscedastic means. *Biometrics*. 1957. 13, 359–364.
32. Bierman, E.L., Amaral, J.A.P., Balknap, B.H., Hyperlipidemia and diabetes mellitus. *Diabetes*. 1975. 25, 509–515.
33. Gilman, A.G., Rall, T.W., Nies, A.S., Tayer, P., Goodman and Gilman's the *Pharmacological Basis of Therapeutics*, eighth ed. Pergamon Press, New York. pp. 1990. 1317–1322.
34. Mazunder, U.K., Gupta, M., Rajeshwar, Y., Antihyperglycaemic effect and antioxidant potential of *Phyllanthus niruri* (Euphorbiaceae) in streptozotocin induced diabetic rats. *Eur. Bull. Drug Res.* 2005. 13, 15–23.
35. Kumar, G., Sharmila Banu, G., Murugesan, A.G., Rajasekara Pandian, M., Antihyperglycaemic and antiperoxidative effect of *Helicteres isora* L. bark extracts in streptozotocin-induced diabetic rats. *J. Appl. Biomed.* 2007a. 5, 97–104.
36. Kumar, G., Sharmila Banu, G., Murugesan, A.G., Rajasekara Pandian, M., Hypoglycaemic effect of *Helicteres isora* barks extract in rats. *J. Ethnopharmacol.* 2006a. 107, 304–307.
37. Loci, A.S., Shaabha, M., Khazraji, A.L., Husain, A., Twaija, A., Hypoglycemic effect of a valuable extract of artemisia herb Alba II. Effect of a valuable extract on some blood parameters in diabetic animals. *J. Ethnopharmacol.* 1994. 43, 167–171.
38. Agardh, C.D., Bjorgell, P., Nilson, E.P., The effect of tolbutamide on lipoproteins, and lipoproteinlipase and hormone sensitive lipase. *Diab. Res. Clin. Pract.* 1999. 46, 99–108.
39. Bopanna, K.N., Kannan, J., Sushma, G., Balaraman, R., Rathod, S.P., Antidiabetic and antihyperlipidemic effect of neem seed, kernel powder on alloxan diabetic rabbits. *Indian J. Pharmacol.* 1997. 29, 162–167.
40. Dario, G., Antonio, C., Giuseppe, P., Oxidative stress and diabetic complications. *Diab. Care* 1996. 19, 257–267.
41. Cohn, R.M., Roth, K.S., Lipid and lipoprotein metabolism. In: *Biochemistry and Disease*, Williams and Wilkins Publishers, Baltimore, 1996. p. 280.
42. Ahmed, M., Shikha, H.A., Sadhu, S.K., Rahman, M.T., Datta, B.K., Diuretic, and anti-inflammatory principle from *Scoparia dulcis*. *Pharmazie*. 2001. 56, 657–660.
43. Sharmila Banu, G., Kumar, G., Rajasekara Pandian, M., Cholesterol lowering activity of the aqueous fruit extract of *Trichosanthes dioica* Roxb. (L.) in normal and streptozotocin diabetic rats. *J. Clin. Diag. Res.* 2007. 1, 561–569.
44. Kumar, G., Murugesan, A.G., Hypolipidaemic activity of *Helicteres isora* L. bark extracts in streptozotocin induced diabetic rats. *J. Ethnopharmacol.* 2008. 116, 161–166.
45. Frayn, K.N., Insulin resistance and lipid metabolism. *Curr. Opin. Lipidol.* 1993. 4, 197–204.
46. Kumar, G., Sharmila Banu, G., Murugesan, A.G., Rajasekara Pandian, M., Effect of *Helicteres isora* bark extracts on brain antioxidant status and lipid peroxidation in streptozotocin diabetic rats. *Pharma. Biol.* 2007b. 45, 753–759.
47. Kumar, G., Sharmila Banu, G., Murugesan, A.G., Rajasekara Pandian, M., Effect of *Helicteres isora* bark extracts on heart antioxidant status and lipid peroxidation in streptozotocin diabetic rats. *J. Appl. Biomed.* 2008a. 6, 89–95.
48. Aragno, M., Tamagno, E., Gatto, V., Brignardello, E., Parola, S., Danni, O., Boccuzzi, G., Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress. *Free Radical Biol. Med.* 1999. 26, 1467–1474.
49. Szkudelski, T., The mechanism of alloxan and streptozotocin action in beta cells of the rat pancreas. *Physiol. Res.* 2001. 50, 536–546.
50. Oberley, L.W., Free radicals and diabetes. *Free Rad. Biol. Med.* 1988. 5, 113–124.
51. Baynes, J.W., Reactive oxygen in the aetiology and complications of diabetes. In: Ioannides, C., Flatt, P.R. (Eds.), *Drug, Diet and Disease, Mechanistic Approach to Diabetes*. 1995. Volume 2. Ellis Horwood Limited, Hertfordshire, pp. 230–231.